Abstract: The disclosure is directed to antibodies and binding fragments thereof that specifically bind FGL2. The disclosure is also directed to uses of the antibodies and binding fragments thereof for treating cancer.

Abstract: The disclosure is directed to antibodies and binding fragments thereof that specifically bind FGL2. The disclosure is also directed to uses of the antibodies and binding fragments thereof for treating cancer.

Abstract: This application relates to methods and compositions for inducing immune tolerance. Specifically, methods and uses of regulatory T cells (Treg) and associated compositions for the induction of immune tolerance are described. The methods and uses may be used to prevent transplant rejection, and in the treatment of diseases or conditions such as graft versus host disease, autoimmune disease and allergies. Also provided are transgenic mice that ubiquitously express FGL2 protein from which the Treg may be isolated.

Abstract: The present disclosure provides a method of treating or preventing hepatic ischemia and reperfusion injury in an animal comprising administering an effective amount of an FGL2-Fc?RIIB inhibitor to an animal in need thereof. Also provided herein are uses, compositions and screening assays for FGL2- Fc?RIIB inhibitors useful in treating hepatic ischemia and reperfusion injury.

Abstract: The disclosure relates to methods for identifying a subject having elevated FGL2 plasma levels, the method comprising the step of assaying a plasma sample from the subject to determine a level of FGL2, wherein a level above control indicates the subject has elevated FGL2 levels. Diagnostic methods, methods of monitoring prognosis and methods of medical treatment relating to viral hepatitis are also provided. The disclosure also provides assays and kits useful in the diagnosis of a viral hepatitis associated with elevated FGL2.

Abstract: An interactive device/system of and method for delivery, receipt and/or decoding of and/or response to keyed or tagged video content provided in connection with one or more video broadcasts (for example, television or streaming video). Responsive thereto, the system and method may deliver and/or receive video and/or audio information. Such delivery and/or receipt of video and/or audio information may be responsive to content embedded in the broadcast but not visually observed, responsive to broadcast content that is visually observed and then parsed and correlated with a predetermined response, and responsive to a user/operator instruction, input and/or request. The interactive video receiving device may determine a video-based broadcast is an interactive video-based broadcast, wherein, the device automatically provides interaction options and or based on a response by the user/viewer to the video-based broadcast, the video receiving device transmits “interest-level” data (i.e.

Abstract: Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a soluble fgl2 protein or a nucleic acid encoding a soluble fgl2 protein. The methods are useful in preventing graft rejection, autoimmune disease, and allergies.

Abstract: Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a soluble fgl2 protein or a nucleic acid encoding a soluble fgl2 protein. The methods are useful in preventing graft rejection, autoimmune disease, and allergies.

Abstract: Methods for mediating immune coagulation using novel antibodies and compounds are described. A protein Fgl2 having direct prothrombinase activity has been identified. Inhibitors of Fgl2 are useful in preventing and treating diseases which require a reduction in immune coagulation including bacterial and viral infections, allograft and xenograft rejection, glomerulonephritis, cancer, a number of gastrointestinal diseases and fetal loss.

Abstract: Interchangeable high band low-noise-amplifiers (LNAs) and low band low-noise-amplifiers (LNAs) and related methods are disclosed that greatly enhance the efficiency of designing handsets for different combinations of frequency bands. The input signals to particular pins on a receiver or transceiver integrated circuit (IC) are swappable such that multiple frequency bands can be input to the same input pins thereby allowing for simplified system design. Efficient programmable techniques are also disclosed for controlling a swap mode within communication ICs. These interchangeable or band swappable input paths, for example, can be utilized to allow interchangeability between high band (PCS, DCS) and low band (GSM, E-GSM) inputs for cellular communications.

Abstract: The present invention relates to porcine fgl2 gene and protein and methods of modulating the gene and protein. The methods are useful in preventing thrombosis associated with the xenotransplantation of porcine organs or tissues.

Abstract: Methods for mediating immune coagulation using novel antibodies and compounds are described. A protein Fgl2 having direct prothrombinase activity has been identified. Inhibitors of Fgl2 are useful in preventing and treating diseases which require a reduction in immune coagulation including bacterial and viral infections, allograft and xenograft rejection, glomerulonephritis, cancer, a number of gastrointestinal diseases and fetal loss.

Abstract: Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a soluble fgl2 protein or a nucleic acid encoding a soluble fgl2 protein. The methods are useful in preventing graft rejection, autoimmune disease, and allergies.

Abstract: The use of Fgl2 inhibitors to treat and control the progression of human Hepatitis B virus-induced hepatitis is described. Inhibitors of Fgl2 include antibodies to Fgl2.

Abstract: Methods for mediating immune coagulation using novel antibodies and compounds are described. A protein Fgl2 having direct prothrombinase activity has been identified. Inhibitors of Fgl2 are useful in preventing and treating diseases which require a reduction in immune coagulation including bacterial and viral infections, allograft and xenograft rejection, glomerulonephritis, cancer, a number of gastrointestinal diseases and fetal loss.

Abstract: The inventor has determined that the nucleocapsid protein from a hepatitis virus can induce the prothrombinase, fgl2. The inventor has further developed that LF-A1 also induces fgl-2. This allows for the development of therapeutic methods and compositions for modulating immune coagulation. In particular, inhibitors of the N-protein or gene or LF-AL protein gene, or LF-A1 binding site on the fgl-2 promoter may be useful in inhibiting immune coagulation caused by a virus such as a hepatitis virus.

Abstract: A knockout mouse in which the Fgl-2 gene has been suppressed is described. The mouse is useful in studying the role of Fgl-2 in normal and disease states including viral hepatitis, allograph rejection, fetal loss, inflammatory bowel disease, lupus glomerulonephritis; acute respiratory disease syndrome, Whipple's disease, cancer and for developing therapies to treat these diseases.

Abstract: Methods for mediating immune coagulation using novel antibodies and compounds are described. A protein Fgl2 having direct prothrombinase activity has been identified. Inhibitors of Fgl2 are useful in preventing and treating diseases which require a reduction in immune coagulation including bacterial and viral infections, allograft and xenograft rejection, glomerulonephritis, cancer, a number of gastrointestinal diseases and fetal loss.

Abstract: Methods for mediating immune coagulation using novel antibodies and compounds are described. A protein Fgl2 having direct prothrombinase activity has been identified. Inhibitors of Fgl2 are useful in preventing and treating diseases which require a reduction in immune coagulation including bacterial and viral infections, allograft and xenograft rejection, glomerulonephritis, cancer, a number of gastrointestinal diseases and fetal loss.

Abstract: Methods for mediating immune coagulation using novel antibodies and compounds are described. A protein Fgl2 having direct prothrombinase activity has been identified. Inhibitors of Fgl2 are useful in preventing and treating diseases which require a reduction in immune coagulation including bacterial and viral infections, allograft and xenograft rejection, glomerulonephritis, cancer, a number of gastrointestinal diseases and fetal loss.